About this trial
This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy. Current MRI scans sometimes miss complete tumor response, which can lead to unnecessary surgery. To address this, researchers will use a special MRI technique called hyperpolarized carbon-13 MRI, along with blood and tissue analysis (metabolomics) and advanced image feature analysis (radiomics). These tools can track how cancer cells use energy and how metabolism changes during treatment.
The study will follow 30 rectal cancer patients at Chang Gung Memorial Hospital over 3 years. Patients will undergo standard MRI, colonoscopy, and advanced metabolic imaging before and after treatment. Results will compare patients whose tumors completely respond to therapy with those who do not. The goal is to see if metabolic changes detected by hyperpolarized MRI and metabolomics can predict treatment outcomes earlier and more accurately. This may help doctors avoid unnecessary surgery and provide more personalized care for rectal cancer patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with biopsy proved rectal adenocarcinoma.
Patents will undergo neoadjuvant chemoradiation therapy (nCRT).
Patients more than 20-year-old.
Disqualifiers
None
Trial population
The study population consists of patients with rectal cancer who received neoadjuvant chemoradiotherapy (nCRT) at a single center. Eligible participants are adults diagnosed with rectal cancer and treated with nCRT prior to surgery.
Trial design
Cohort
Prospective
Treatments tested in this trial
Hyperpolarized 13C-MRI (HP 13C-MRI)
DrugMetabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
Treatment groups
Trial outcomes
Primary outcomes
Metabolic activity in spleen measured as pyruvate-to-lactate conversion rate
The pyruvate-to-lactate conversion calculated by kinetic modeling-based conversion rate of pyruvate-to-lactate (kPL) and model-free metric (signal-to-noise ratio and area-under-curve).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Chang Gung Memorial Hospital
Lead sponsor
Ministry of Science and Technology, Taiwan
Collaborator